Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Indaptus Therapeutics Inc INDP

Healthcare Biotechnology
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be... see more

Recent & Breaking News (NDAQ:INDP)

Indaptus Therapeutics to Present at JMP Securities Life Sciences Conference

GlobeNewswire June 9, 2022

Indaptus Therapeutics to Present at Jefferies Healthcare Conference

GlobeNewswire June 3, 2022

Enlivex Appoints Dr. Roger J. Pomerantz to its Board of Directors as Vice Chairman

GlobeNewswire May 23, 2022

Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors

GlobeNewswire May 19, 2022

Indaptus Therapeutics to Present at H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

Indaptus Therapeutics to Present at 2nd Annual Chronic HBV Drug Development Summit

GlobeNewswire April 20, 2022

Indaptus Therapeutics to Present at Maxim Group 2022 Virtual Growth Conference

GlobeNewswire March 23, 2022

Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update

GlobeNewswire March 21, 2022

Indaptus Therapeutics to Present at 3rd Annual STING & TLR-Targeting Therapies Summit

GlobeNewswire March 17, 2022

Indaptus Therapeutics to Present at 34th Annual ROTH Conference

GlobeNewswire March 7, 2022

Indaptus Therapeutics to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

GlobeNewswire January 5, 2022

Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer

GlobeNewswire January 3, 2022

Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of Directors

GlobeNewswire December 1, 2021

Indaptus Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire November 15, 2021

Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent

GlobeNewswire September 15, 2021

Intec Closes Merger with Decoy Biosystems

PR Newswire August 3, 2021

Intec Announces Expected Closing Date of Decoy Merger

PR Newswire August 3, 2021

Intec Announces $30 Million Private Placement Ahead of Decoy Merger

PR Newswire July 26, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates PRAH, WSFS, STAY, NTEC, MX; Shareholders are Encouraged to Contact the Firm

PR Newswire May 13, 2021